DGAP-News: CereSpir Incorporated Secures Exclusive Worldwide Development and Commercialization Rights for CHF 5074 From Chiesi Farmaceutici S.p.A.
(firmenpresse) - CereSpir Incorporated
08.11.2013 15:00
---------------------------------------------------------------------------
NEW YORK and PARMA, Italy, 2013-11-08 15:00 CET (GLOBE NEWSWIRE) --
CereSpir(tm) Incorporated and Chiesi Farmaceutici S.p.A. today announced CereSpir
has acquired the worldwide development and commercialization rights to CHF
5074, a novel, first-in-class small molecule microglia modulator discovered and
developed by Chiesi researchers. Chiesi has demonstrated CHF 5074 improves
cognition and reduced brain inflammation in patients with mild cognitive
impairment (MCI). CereSpir now assumes all development and commercialization
activities for CHF 5074.
'In the past year, scientists, clinicians, and drug developers have gained a
significant amount of knowledge about Alzheimer's disease and MCI. CHF 5074
represents the right asset at the right time with the right team to move it
into Phase 3 clinical trials,' stated Daniel Chain, PhD, Chairman and CEO of
CereSpir. 'The more we learn about its multi-target neuroprotective mechanism
of action, which is supported by the latest discoveries from academia, the more
excited we become about CHF 5074 as a potential game changer in the fight
against Alzheimer's.'
'The Chiesi Group has been investing in the development of CHF 5074 up to phase
2 completion, getting more and more confident of its potential in the treatment
of MCI. CereSpir will now be able to leverage these early clinical findings and
know how to advance the program,' underlined Paolo Chiesi, Chiesi Group Vice
President and Research&Development Director. 'We trust this agreement will
expedite the clinical development of this new therapeutic agent to the benefit
of patients and their families.'
Reflecting its confidence in CHF 5074 and in the partnership with CereSpir, the
Chiesi Group has reserved the possibility to contribute to the future
manufacturing and eventual commercialization of the drug that might derive from
the development of the molecule.
Mintz Levin Cohn Ferris Glovsky and Popeo PC represented CereSpir in
negotiating this transaction.
About CHF 5074
CHF 5074 is a small molecule with a unique microglial modulating mechanism of
action capable of selectively reducing pro-inflammatory activities of
microglial cells while increasing their ability to remove neurotoxic amyloid
beta ('Abeta') aggregates in the brain by phagocytosis. Microglia are small cells
that migrate through the brain to remove waste products, such as amyloid
aggregates that cause inflammation and irreversible damage to nerve cells.
Chronic dysfunction of microglia is increasingly believed to play an important
role at the very beginnings of Alzheimer's disease. The results from Chiesi's
human clinical studies corroborate the large body of data from published
preclinical studies. In Alzheimer's disease transgenic mouse models, CHF 5074
was shown to reduce neuroinflammation, inhibit brain amyloid beta plaque deposits,
reduce tau pathology, and reverse associated memory deficits. These findings
indicate CHF 5074 acts simultaneously on several important therapeutic targets,
and this neuroprotective multi-target approach may translate into preventing
the memory loss that is the hallmark of Alzheimer's disease.
About Alzheimer's disease, ApoE4, and Mild Cognitive Impairment
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease and
the leading cause of dementia among the elderly. More than 30 million people
have been diagnosed with AD, and the associated costs of care estimates exceed
$200 billion annually. Today, AD remains the largest unmet medical need in
neurology, with the disease expected to afflict 100 million people globally by
2050.
Individuals who have the ApoE4 gene are three to eight times more likely to
develop AD than those who do not carry ApoE4. People who have two copies of the
ApoE4 gene are at even greater risk than those with a single copy of ApoE4
copy. The ApoE4 gene causes a more aggressive form of AD that is believed to
involve a strong inflammatory response.
Mild Cognitive Impairment (MCI) causes cognitive changes that are serious
enough to be noticed by the individuals experiencing them or to other people,
but the changes are not severe enough to interfere with daily life or
independent function; therefore they do not meet diagnostic guidelines for
dementia. However, those with MCI, particularly if they also carry the ApoE4
gene, have an increased risk of eventually developing Alzheimer's or another
type of dementia.
About Chiesi Farmaceutici S.p.A.
Founded in 1935 in Parma (Italy), the Chiesi Group achieved in 2012 a turnover
of [Eur] 1,107 million, an increase of 4.7% in comparison with the previous year.
The Group, whose main areas of activity are in respiratory therapies and
specialist medicine, currently has 25 branches worldwide and is present in over
60 countries with its products, produced at the plants in Parma, Blois (France)
and Santana de Parnaiba (Brazil).
In 2012 investment in R&D reached [Eur] 198 million, accounting for 18% of sales, a
level that the company intends to maintain in coming years. The R&D operations
in Parma, Paris, Rockville (USA) and Chippenham (UK) integrate their efforts to
advance the Group's pre-clinical, clinical and registration programs. At the
end of 2012, the Chiesi Group employed over 3,800 people and more than 350 of
them were involved in R&D.
About CereSpir Incorporated
CereSpir is dedicated to preserving the primary essence of each person, his or
her memories. The Company holds the exclusive worldwide development and
commercialization rights to CHF 5074, a novel, first-in-class small molecule
microglial modulator, from Chiesi Farmaceutici S.p.A. Upon receiving further
input from the U.S. Food and Drug Administration, CereSpir anticipates
initiating a Phase 3 clinical trial to determine if CHF 5074 has the potential
to become the first therapy for people with ApoE4 genotype and amnestic Mild
Cognitive Impairment (MCI). The Company's ultimate goal is to start treating
patients with CHF 5074 before amyloid plaques develop as a prevention strategy
for Alzheimer's disease.
CONTACT: MEDIA AND INSTITUTIONAL INVESTOR CONTACT:
Juliane Snowden
The Oratorium Group, LLC
jsnowden(at)oratoriumgroup.com
+1 646-438-9754
News Source: NASDAQ OMX
08.11.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: CereSpir Incorporated
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9902719759
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.11.2013 - 15:00 Uhr
Sprache: Deutsch
News-ID 314464
Anzahl Zeichen: 4160
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 348 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: CereSpir Incorporated Secures Exclusive Worldwide Development and Commercialization Rights for CHF 5074 From Chiesi Farmaceutici S.p.A."
steht unter der journalistisch-redaktionellen Verantwortung von
CereSpir Incorporated (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
